Core revenue contracted and cash generation deteriorated despite non-cash fair value gains masking the loss. The upcoming C$46.4M restricted cash release provides near-term liquidity, but the structural revenue decline from Canadian reimbursement cuts and consumer exit is a key risk. Management expects sequential revenue and EBITDA growth in Q2 — watch for confirmation. The persistent ICFR weakness adds governance overhang. The ATM program (U.S. $87.1M remaining) dilutes further.
Price Chart
Executive Summary
Aurora Cannabis reported Q1 FY2027 net revenue of C$67.6M, down 8.8% YoY, driven by a C$7.0M decline in Canadian medical cannabis revenue due to a 30% federal reimbursement cut and the wind-down of the consumer cannabis business. Net loss from continuing operations improved to C$4.0M from C$10.2M, but adjusted EBITDA fell 68% to C$3.4M and operating cash flow turned negative at (C$4.4M). The company disclosed a material weakness in internal controls over financial reporting and continued ATM dilution (1.58M shares sold at C$4.29). A subsequent approval to wind up the segregated cell program will unlock ~C$46.4M of restricted cash, improving liquidity.
Key Facts
- Net revenue of C$67.6M for Q1 FY2027 vs C$74.1M in Q1 FY2026, an 8.8% decline.
- Canadian medical net revenue fell to C$20.7M from C$27.7M due to a 30% reduction in federal reimbursement rates effective April 1, 2026.
- International medical net revenue grew to C$43.3M from C$37.1M, driven by higher sales in Germany.
- Net loss from continuing operations improved to C$4.0M vs C$10.2M in the prior year period.
- Adjusted EBITDA fell to C$3.4M from C$10.8M YoY.
- Operating cash flow from continuing operations was negative C$4.4M vs positive C$7.7M a year earlier.
- Free cash flow was negative C$5.8M vs positive C$6.8M.
- Gross margin before fair value adjustments decreased to 43% from 52%.
- The company disclosed a material weakness in ICFR over biological assets and inventory valuation.
- 1,577,330 shares were sold under the ATM program at an average price of C$4.29 for gross proceeds of C$6.8M.
- Acquired Safari Flower Company for C$15M cash and 2.4M shares, adding EU-GMP capacity.
- Subsequent to quarter end, Board approved wind-up of segregated cell program, unlocking ~C$46.4M in restricted cash by Q3 FY2027.
Financial Impact
Net revenue declined C$6.5M (-8.8%) YoY; adjusted EBITDA declined C$7.4M (-68%); operating cash flow swung negative by C$12.1M from positive to negative.
Risk Factors
- Further Canadian medical reimbursement cuts could pressure revenue and margins.
- Persistent material weakness in ICFR over biological asset and inventory valuation may erode investor confidence.
- Negative operating cash flow and free cash flow raise concerns about sustainability without additional financing or ATM sales.
- Dilution from the ATM program (U.S. $87.1M remaining capacity).
- Integration risk from Safari acquisition and planned capital expenditures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-052911 |
| Document: mda20260630q12027.htm | 0001628280-26-052911 |
| Document: form6-k20260630q12027.htm | 0001628280-26-052911 |
| Document: a993certificationofceo.htm | 0001628280-26-052911 |
| Document: a994certificationofcfo.htm | 0001628280-26-052911 |
| Document: 0001628280-26-052911-index-headers.html | 0001628280-26-052911 |
| Document: 0001628280-26-052911-index.html | 0001628280-26-052911 |
| Document: 0001628280-26-052911.txt | 0001628280-26-052911 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.87 | awaiting T+5 | — | $3.90 (+0.78%) |
Oct 14, 2026 12d ago | 6-K | $4.10 $3.97 | ▼ −3.17% | ▼ −2.16% | $3.90 (−4.88%) |
Oct 8, 2026 18d ago | 6-K | $4.43 $4.10 | ▼ −7.45% | ▼ −7.17% | $3.90 (−11.96%) |
Oct 6, 2026 20d ago | 6-K | $4.46 $4.17 | ▼ −6.50% | ▼ −5.52% | $3.90 (−12.56%) |
Oct 5, 2026 21d ago | 6-K | $4.59 $4.29 | ▼ −6.54% | ▼ −6.40% | $3.90 (−15.03%) |
Sep 16, 2026 5w ago | 6-K | $3.83 $4.22 | ▲ +10.18% | ▲ +7.62% | $3.90 (+1.83%) |
Sep 14, 2026 6w ago | 6-K | $3.81 $4.03 | ▲ +5.77% | ▲ +5.67% | $3.90 (+2.36%) |
Sep 9, 2026 6w ago | 6-K | $3.88 $3.83 | ▼ −1.29% | ▼ −0.63% | $3.90 (+0.52%) |
Sep 2, 2026 7w ago | 6-K | $4.03 $3.73 | ▼ −7.44% | ▼ −6.49% | $3.90 (−3.23%) |
Aug 24, 2026 9w ago | 6-K | $3.94 $4.05 | ▲ +2.79% | ▲ +2.32% | $3.90 (−1.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers